Skip to Content
Merck
CN
  • Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain.

Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain.

Brain research (1995-11-06)
L Ginsberg, S Rafique, J H Xuereb, S I Rapoport, N L Gershfeld
ABSTRACT

A significant and selective deficiency of ethanolamine plasmalogen (PPE) relative to phosphatidylethanolamine was identified in post mortem brain samples from patients with Alzheimer's disease (AD). This lipid defect showed anatomic specificity, being more marked at a site of neurodegeneration in AD brain than in a region relatively spared by the disease (mid-temporal cortex vs. cerebellum) and disease specificity for AD: it was not observed at the primary site of neurodegeneration in Huntington's disease (caudate nucleus) nor Parkinson's disease (substantia nigra). PPE deficiency parallels an inherent tendency towards membrane bilayer instability previously detected in AD brain which is necessarily due to a change in membrane lipid composition, and which may contribute to AD pathogenesis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ethanolamine, ACS reagent, ≥99.0%
Sigma-Aldrich
Ethanolamine, purified by redistillation, ≥99.5%
Supelco
Ethanolamine, analytical standard
Sigma-Aldrich
Ethanolamine, puriss. p.a., ACS reagent, ≥99.0% (GC/NT)
Sigma-Aldrich
Ethanolamine, ≥98%
Sigma-Aldrich
Ethanolamine, liquid, BioReagent, suitable for cell culture, ≥98%
Sigma-Aldrich
2-AMINOETHANOL>= 99 % | 141-43-5, ≥99%